Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Phase 2 symbols : Ayla save search
Ayala Pharmaceuticals Presents Updated AL102 Results from Phase 2 Clinical Trial in Desmoid Tumors at ESMO Congress 2023
Published: 2023-10-23 (Crawled : 11:00) - globenewswire.com
BMY | $48.295 -0.01% 920K
|
Health Technology
|
| O: -0.19%
H: 0.66%
C: -0.62%
ADXS | $0.57 9.5K
|
Health Technology
|
| O: 0.0%
H: 5.56%
C: 0.0%
al102 congress tumors pharmaceuticals trial results phase 2
Ayala Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA Regarding AL102 for the Treatment of Desmoid Tumors
Published: 2023-07-05 (Crawled : 12:00) - globenewswire.com
BMY | $48.295 -0.01% 920K
|
Health Technology
|
| O: -0.19%
H: 1.07%
C: 0.65%
ADXS | $0.57 9.5K
|
Health Technology
|
| O: 1.24%
H: 0.0%
C: -7.09%
al102 fda tumors treatment pharmaceuticals meeting phase 2
Updated RINGSIDE Phase 2 Results Featured in Poster Discussion Session at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
Published: 2023-06-05 (Crawled : 12:00) - globenewswire.com
BMY | $48.295 -0.01% 920K
|
Health Technology
|
| O: 0.37%
H: 0.85%
C: 0.12%
ADXS | $0.57 9.5K
|
Health Technology
|
| O: -2.73%
H: 4.42%
C: -0.4%
meeting results phase 2
Ayala Pharmaceuticals Announces Updated RINGSIDE Phase 2 Results at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
Published: 2023-05-25 (Crawled : 21:00) - globenewswire.com
BMY | $48.295 -0.01% 920K
|
Health Technology
|
| O: -0.08%
H: 0.71%
C: -1.07%
ADXS | $0.57 9.5K
|
Health Technology
|
| O: 1.01%
H: 17.5%
C: -15.0%
pharmaceuticals meeting results phase 2
Ayala Pharmaceuticals Announces Continuation of RINGSIDE Phase 2/3 Study in Desmoid Tumors Following Recommendation of Independent Data Monitoring Committee
Published: 2023-03-03 (Crawled : 13:00) - globenewswire.com
ADXS | $0.57 9.5K
|
Health Technology
|
| O: -11.72%
H: 35.16%
C: 35.16%
pharmaceuticals continuation tumors study phase 2
Ayala Pharmaceuticals Presents Positive Interim Data from RINGSIDE Pivotal Phase 2/3 Trial of AL102 in Desmoid Tumors at ESMO Congress 2022
Published: 2022-09-12 (Crawled : 14:20) - biospace.com/
AYLA | $0.5036 5.84% -0.7% 0
|
Health Technology
|
| O: 4.23%
H: 0.81%
C: -28.93%
al102 trial positive phase 2
Ayala Pharmaceuticals Announces Interim Data from Part A of the Phase 2/3 RINGSIDE Trial of AL102 in Desmoid Tumors
Published: 2022-07-05 (Crawled : 13:20) - biospace.com/
AYLA | $0.5036 5.84% -0.7% 0
|
Health Technology
|
| O: -0.24%
H: 3.6%
C: -1.79%
al102 trial phase 2
Ayala Pharmaceuticals Announces Completion of Enrollment in Part A of RINGSIDE, a Pivotal Phase 2/3 Study of AL102 in Desmoid Tumors
Published: 2022-02-23 (Crawled : 22:00) - globenewswire.com
AYLA | $0.5036 5.84% -0.7% 0
|
Health Technology
|
| O: -4.52%
H: 7.35%
C: -4.98%
al102 phase 2 als phase 2/3 enroll
Ayala Pharmaceuticals Announces Completion of Enrollment in Part A of RINGSIDE, a Pivotal Phase 2/3 Study of AL102 in Desmoid TumorsInterim Results expected mid-2022
Published: 2022-02-23 (Crawled : 19:00) - biospace.com/
AYLA | $0.5036 5.84% -0.7% 0
|
Health Technology
|
| O: -4.52%
H: 7.35%
C: -4.98%
al102 phase 2 als phase 2/3 enroll
Ayala Pharmaceuticals Presents Preliminary Clinical Data from the Ongoing Phase 2 ACCURACY Trial and Announces Pre-Clinical Proof of Concept Data for Enhanced Activity of AL101 in Combination with Approved Cancer Therapies in ACC
Published: 2021-09-16 (Crawled : 14:00) - biospace.com/
BMY | $48.295 -0.01% 920K
|
Health Technology
|
| O: -0.23%
H: 0.31%
C: -1.02%
AYLA | $0.5036 5.84% -0.7% 0
|
Health Technology
|
| O: 0.71%
H: 5.25%
C: -14.35%
phase 2 ongoing pre-clinical cancer proof of concept trial preclinical
Ayala Pharmaceuticals to Present Clinical Data from Ongoing Phase 2 ACCURACY Trial and New Preclinical Results from Combination Study of AL101 at the European Society for Medical Oncology (ESMO) Virtual Congress 2021
Published: 2021-09-01 (Crawled : 12:15) - globenewswire.com
BMY | $48.295 -0.01% 920K
|
Health Technology
|
| O: 0.64%
H: 0.0%
C: -2.2%
AYLA | $0.5036 5.84% -0.7% 0
|
Health Technology
|
| O: -2.6%
H: 6.97%
C: 6.81%
phase 2 europe ongoing results trial preclinical pre-clinical
Ayala Pharmaceuticals Announces First Patient Dosed in Phase 1 Clinical Trial of AL102 in Combination with BCMA Targeting Agent, WVT078, in Patients with relapsed/refractory Multiple Myeloma
Published: 2021-04-21 (Crawled : 13:15) - ayalapharma.com
AYLA | $0.5036 5.84% -0.7% 0
|
Health Technology
|
| O: 0.0%
H: 3.24%
C: 0.1%
phase 1 trial phase 3 phase 2
Ayala Pharmaceuticals Announces First Patient Dosed in Phase 2 TENACITY Clinical Trial of AL101 for the Treatment of Patients with Notch-Activated Triple Negative Breast Cancer
Published: 2021-01-28 (Crawled : 15:01) - globenewswire.com
AYLA | $0.5036 5.84% -0.7% 0
|
Health Technology
|
| O: -9.93%
H: 10.29%
C: 5.55%
cancer treatment phase 2 breast cancer trial
Ayala Pharmaceuticals to Accelerate Development of AL102 for the Treatment of Desmoid Tumors in Pivotal Phase 2/3 Study
Published: 2021-01-04 (Crawled : 13:03) - globenewswire.com
AYLA | $0.5036 5.84% -0.7% 0
|
Health Technology
|
| O: 7.21%
H: 1.76%
C: -4.52%
treatment phase 2 phase 2/3
Gainers vs Losers
| 81% | 19% |
Top 10 Gainers
AGBA | News | $1.37 242.5% 76M
|
Finance
EGOX | $0.0835 131.94% 160M
|
ZCMD | $2.18 50.35% 24M
|
Commercial Services
CHRO | $1.73 41.22% 46K
|
n/a
RWOD | $10.61 32.68% 5.1M
|
n/a
NVFY | $2.77 31.28% 2.2M
|
Consumer Durables
AULT | $0.3174 31.1% 28M
|
Manufacturing
WISA 4 | $7.11 20.71% 4.7M
|
Electronic Technology
LIFW | News | $0.99 19.26% 800K
|
Administrative and Support and ...
PRTG | $0.285 18.75% 140K
|
Mining, Quarrying, and Oil and ...
Your saved searches
Save your searches and get alerts when important news are released.